Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (RAP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Duke University
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Herbert Hurwitz, MD, Duke University Medical Center Identifier:
First received: February 2, 2010
Last updated: July 5, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)